The Year Ahead: Controversial NDAs Could Entangle FDA In ‘08; Where Are The Oncologics?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Looking ahead at FDA’s review calendar for 2008, the agency will be wrestling with several enigmatic decisions as it considers applications for fibromyalgia and chronic fatigue syndrome, controversial diseases with nebulous definitions and diagnoses.
You may also be interested in...
Savella's Secret? "Unknown Factor" Could Be Key To Symptom Relief
The effect of Forest’s fibromyalgia therapy Savella (milnacipran) on a composite responder endpoint in Phase III did not correspond to the results for individual components of that endpoint, an "unusual finding" that the reviewing FDA division director suggested could result from the drug’s effect on an "unknown factor."
Hemispherx Ampligen Amendment Will Jumpstart NDA Clock
Biopharma prepares to respond to all 14 deficiencies cited in FDA’s refuse-to-file letter for the Toll-like receptor-3 agonist. Firm also exploring drug’s use as an adjuvant for HIV/AIDS and avian influenza vaccines
Hemispherx Ampligen Amendment Will Jumpstart NDA Clock
Biopharma prepares to respond to all 14 deficiencies cited in FDA’s refuse-to-file letter for the Toll-like receptor-3 agonist. Firm also exploring drug’s use as an adjuvant for HIV/AIDS and avian influenza vaccines